Nyxoah SA (NYXH) Form 6-K — Oct 20, 2026
Nyxoah reported preliminary Q3 2026 global net revenue of approximately €9.2 million, up 19% sequentially, with U.S. revenue of €6.7 million growing 29% sequentially. The company cut its full year 2026 revenue guidance to €33-35 million from €36-40 million previously, citing a U.S. ramp more reflective of historical ramps for new technology.
Key figures
- Revenue
- €9.2 million (Q3 2026 preliminary global net revenue)
- Guidance
- Full year 2026 global net revenue of €33-35 million, cut from €36-40 million previously
- Cash Position
- ~€77.0 million as of September 30, 2026
- Us net revenue
- €6.7 million
- Us sequential growth
- 29%
- Total surgeons trained
- 342
- New surgeons trained q3
- 80
- Global sequential growth
- 19%
- New accounts activated q3
- 53
- Active high volume accounts
- 233
- Acccess 12mo ahi responder rate
- 77.2% (p<0.001)
- Patients under prior authorization
- 447
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.